O-glycosylated peptides, including Contulakin G, with therapeutic potential for treatment of pain and seizure
This technology comprises O-glycosylated cyclic peptides, including contulakin- G and derivatives isolated from cone snail venom. These show promise as therapeutics for pain, seizures, and other indications, and have an attractive safety profile.
Potential therapeutic applications include treatment of pain, seizure, and use as an antipsychotic.
� Estimates suggest that pain costs the American public $100 billion/year in health care, compensation, and litigation.
� Currently available treatments include opioids, which have significant side effects, and NSAIDS, which are ineffective against moderate to severe pain.
� Undesirable side effects of current treatments include GI discomfort, sedation, ataxia, and cognitive impairment.
Stage of Development
The following issued U.S. Patents pertain to composition of matter and therapeutic uses of these peptides: 5,432,155; 6,696,408; 6,369,193; 6,344,551; 5,700,778; and 6,489,298
� Craig, A.G. et al., (1999) J. Biol. Chem., 274: 13752�13759
� Kern, S.E. et al., (2007) Anesth. Analg., 104:1514 �20.
� Allen, J.W. et al., (2007) Anesth. Analg., 104:1505�13.
� Olivera Lab Webpage, http://www.biology.utah.edu/faculty2.php?inum=7
Fe Abogadie, John Dykert, Doju Yoshikami, Robert Jones, A. Grey Craig, Jean E.F. Rivier, William Gray, Chris Hopkins, Baldomero Olivera, Lourdes Cruz, Ki-Joon Shon, Michelle Grilley, John Wagstaff, David Hillyard, Josep Torres, Glenn Zafara, et al
Type of Offer:
« More Life Sciences Patents